MedicarePartD.guide

A non-government resource built from CMS public data

HIV treatment and prevention on every 2026 Idaho Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in Idaho cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days
HIV treatment and prevention by 2026 Idaho Part D plan
DrugHumana Basic Rx Plan$0.00/moS5884-147Wellcare Value Script$9.60/moS4802-162Humana Value Rx Plan$19.40/moS5884-210Wellcare Classic$23.70/moS4802-021SilverScript Choice$27.70/moS5601-062HealthSpring Extra Rx$56.30/moS5617-381AARP Medicare Rx Saver from UHC$56.50/moS5921-375Humana Premier Rx Plan$115.50/moS5884-177HealthSpring Assurance Rx$128.60/moS5617-153AARP Medicare Rx Preferred from UHC$132.60/moS5921-412
Biktarvybictegravir/emtricitabine/tenofovir alafenamideTier 525%QL 30/30dTier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 533%QL 30/30dTier 525%Tier 531%QL 30/30d
Dovatodolutegravir and lamivudineTier 525%QL 30/30dTier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 533%QL 30/30dTier 525%Tier 531%QL 30/30d
Triumeqabacavir/dolutegravir/lamivudineTier 433%QL 180/30dTier 440%Tier 432%QL 180/30dTier 427%Tier 435%Tier 431%QL 300/30dTier 435%QL 180/30dTier 450%QL 180/30dTier 430%QL 300/30dTier 436%QL 180/30d
Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamideTier 525%QL 30/30dTier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 533%QL 30/30dTier 525%QL 30/30dTier 531%QL 30/30d
Odefseyemtricitabine/rilpivirine/tenofovir alafenamideTier 525%QL 30/30dTier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 533%QL 30/30dTier 525%QL 30/30dTier 531%QL 30/30d
Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamideTier 525%QL 30/30dTier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 533%QL 30/30dTier 525%Tier 531%QL 30/30d
Julucadolutegravir and rilpivirineTier 525%QL 30/30dTier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 533%QL 30/30dTier 525%Tier 531%QL 30/30d
Descovyemtricitabine and tenofovir alafenamideTier 525%QL 30/30dTier 525%QL 30/30dTier 526%QL 30/30dTier 525%QL 30/30dTier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 533%QL 30/30dTier 525%QL 30/30dTier 531%QL 30/30d
Truvadaemtricitabine and tenofovir disoproxilNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
emtricitabine-tenofovirgeneric TruvadaTier 433%QL 30/30dTier 440%QL 30/30dTier 432%QL 30/30dTier 427%QL 30/30dTier 435%QL 30/30dTier 431%QL 30/30dTier 435%QL 30/30dTier 450%QL 30/30dTier 430%QL 30/30dTier 436%QL 30/30d
TivicaydolutegravirTier 525%QL 60/30dTier 525%Tier 526%QL 60/30dTier 525%Tier 525%Tier 431%QL 180/30dTier 525%QL 60/30dTier 533%QL 60/30dTier 430%QL 180/30dTier 531%QL 60/30d

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.